

Maria Teresa Fierro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7658291/publications.pdf>

Version: 2024-02-01

76
papers

1,138
citations

331670

21
h-index

454955

30
g-index

77
all docs

77
docs citations

77
times ranked

1626
citing authors

#	ARTICLE	IF	CITATIONS
1	Guttate psoriasis in a patient with mycosis fungoides in treatment with Brentuximab vedotin: An unreported association. <i>Dermatologic Therapy</i> , 2022, , e15309.	1.7	1
2	S�zary Syndrome: Different Erythroderma Morphological Features with Proposal for a Clinical Score System. <i>Cells</i> , 2022, 11, 333.	4.1	1
3	CD38 Expression by Circulating and Skin-Infiltrating Lymphocytes from Sezary Syndrome Patients: A Flow Cytometry and Immunohistochemistry Study. <i>Disease Markers</i> , 2022, 2022, 1-7.	1.3	2
4	Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study. <i>Dermatologic Therapy</i> , 2022, 35, e15492.	1.7	3
5	Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or S�zary Syndrome. <i>Journal of Investigative Dermatology</i> , 2021, 141, 484-495.	0.7	31
6	Lack of detection of Cutavirus DNA using PCR real time in cutaneous T-cell lymphomas. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2021, 155, 772-774.	0.8	4
7	Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: experience from an Italian skin cancer unit. <i>Future Oncology</i> , 2021, 17, 759-761.	2.4	5
8	Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA�COVID-19 registry. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1813-1824.	5.7	28
9	Prognostic and Predictive Biomarkers in Stage III Melanoma: Current Insights and Clinical Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4561.	4.1	21
10	Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review. <i>Oncotarget</i> , 2021, 12, 1116-1121.	1.8	9
11	Infections in S�zary syndrome: A retrospective cohort study of 113 patients. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	2
12	CD27 mRNA expression in mycosis fungoides. <i>Italian Journal of Dermatology and Venereology</i> , 2021, , .	0.2	0
13	Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives. <i>Frontiers in Oncology</i> , 2021, 11, 733770.	2.8	13
14	Non-Sentinel Lymph Node Detection during Sentinel Lymph Node Biopsy in Not-Complete-Lymph-Node-Dissection Era: A New Technique for Better Staging and Treating Melanoma Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 4319.	2.4	2
15	Nutritional Interventions for Patients with Melanoma: From Prevention to Therapy��An Update. <i>Nutrients</i> , 2021, 13, 4018.	4.1	6
16	Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials. <i>Journal of Clinical Medicine</i> , 2021, 10, 5475.	2.4	8
17	Melanoma Management during the COVID-19 Pandemic Emergency: A Literature Review and Single-Center Experience. <i>Cancers</i> , 2021, 13, 6071.	3.7	11
18	A meta-analysis of melanoma risk in industrial workers. <i>Melanoma Research</i> , 2020, 30, 286-296.	1.2	5

#	ARTICLE	IF	CITATIONS
19	Efficacy of dupilumab in prurigo nodularis in elderly patient. <i>Dermatologic Therapy</i> , 2020, 33, e13201.	1.7	25
20	Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19. <i>Seminars in Oncology</i> , 2020, 47, 302-304.	2.2	15
21	Case of bladder cancer during Dupilumab therapy: Just an incidental event?. <i>Dermatologic Therapy</i> , 2020, 33, e13854.	1.7	5
22	Moderate to severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak. <i>Dermatologic Therapy</i> , 2020, 33, e13680.	1.7	11
23	Evolution of different clinical patterns of cutaneous lesions in a suspected COVID-19 patient. <i>European Journal of Dermatology</i> , 2020, 30, 747-748.	0.6	2
24	COVID-19 infection and dermatologic surgery: management in a dermo-oncology center in a high-risk pandemic area. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 684-685.	0.8	1
25	A traveller's wart: tungiasis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 236-237.	0.8	1
26	Is HERV-K and HERV-W expression regulated by mir-155 in Sjögren Syndrome?. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 477-482.	0.8	1
27	Tocilizumab and its usage for skin diseases. <i>Italian Journal of Dermatology and Venereology</i> , 2020, , .	0.2	0
28	Genetic mutations in primary malignant melanoma of the esophagus: case report and literature review. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 680-682.	0.8	1
29	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 121, 144-153.	2.8	27
30	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 119, 168-178.	2.8	61
31	Identification of Risk Factors for Multiple Non-Melanoma Skin Cancers in Italian Kidney Transplant Recipients. <i>Medicina (Lithuania)</i> , 2019, 55, 279.	2.0	6
32	TERT Promoter Mutations are Associated with Visceral Spreading in Melanoma of the Trunk. <i>Cancers</i> , 2019, 11, 452.	3.7	17
33	BRAF/MEK inhibitors in patients with metastatic melanoma: predictive factors of complete response. <i>Future Oncology</i> , 2019, 15, 133-139.	2.4	1
34	Primary cutaneous B-cell lymphoma: narrative review of the literature. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 466-479.	0.8	6
35	The large spectrum of Spitzoid tumors: a retrospective survival study. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 315-320.	0.8	3
36	Autoimmune connective tissue diseases and pregnancy. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 263-276.	0.8	1

#	ARTICLE	IF	CITATIONS
37	BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti-“PD-1 Antibody. <i>Clinical Cancer Research</i> , 2018, 24, 3377-3385.	7.0	31
38	Sentinel lymph node biopsy versus observation in thick melanoma: A multicenter propensity score matching study. <i>International Journal of Cancer</i> , 2018, 142, 641-648.	5.1	20
39	ALK expression favorably impacts the prognosis of NRAS-“mutated metastatic melanomas. <i>Oncology Letters</i> , 2018, 16, 7091-7096.	1.8	1
40	DNA from Human Polyomaviruses, MWPvV, HPyV6, HPyV7, HPyV9 and HPyV12 in Cutaneous T-cell Lymphomas. <i>Anticancer Research</i> , 2018, 38, 4111-4114.	1.1	9
41	Co-isolation and analysis of extracellular vesicle (EV)-associated DNA and cell free DNA (cfDNA) to improve the diagnostic and prognostic value of circulating BRAF V600E in metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21564-e21564.	1.6	0
42	Prognostic role of maspin expression in melanoma: probably far from clinical use. <i>Histopathology</i> , 2017, 71, 158-162.	2.9	2
43	Role of interferon in melanoma: old hopes and new perspectives. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 475-483.	3.1	21
44	Treatment of metastatic melanoma: a multidisciplinary approach. <i>Italian Journal of Dermatology and Venereology</i> , 2017, 152, 241-261.	0.2	4
45	Prognostic role of histological regression in cutaneous melanoma. <i>Italian Journal of Dermatology and Venereology</i> , 2017, 152, 638-641.	0.2	0
46	Primary cutaneous B-“cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers. <i>Cancer Medicine</i> , 2016, 5, 2740-2755.	2.8	34
47	The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 736-739.	1.2	36
48	Metastatic sebaceous cell carcinoma, review of the literature and use of electrochemotherapy as possible new treatment modality. <i>Radiology and Oncology</i> , 2016, 50, 308-312.	1.7	10
49	Melanoma of the lower extremities: foot site is an independent risk factor for clinical outcome. <i>International Journal of Dermatology</i> , 2015, 54, 1023-1029.	1.0	13
50	Spiky follicular mycosis fungoides: a clinicopathologic study of 8 cases. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 164-172.	1.3	27
51	Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1491-1500.	3.1	6
52	Association of Histologic Regression in Primary Melanoma With Sentinel Lymph Node Status. <i>JAMA Dermatology</i> , 2015, 151, 1301.	4.1	61
53	Blood Flow Cytometry in S-“zary Syndrome. <i>American Journal of Clinical Pathology</i> , 2015, 143, 57-69.	0.7	45
54	Gauze-“based negative pressure wound therapy: a valid method to manage pyoderma gangrenosum. <i>International Wound Journal</i> , 2014, 11, 164-168.	2.9	23

#	ARTICLE	IF	CITATIONS
55	Functional and Phenotypical Impairment of Polymorphonuclear Cells in Atopic Dermatitis: An Additional Cause for the Known Susceptibility to Infections?. <i>Dermatology</i> , 2012, 224, 323-330.	2.1	7
56	Functional and phenotypical alterations of polymorphonuclear cells in SÅ©zary syndrome patients. <i>European Journal of Dermatology</i> , 2011, 21, 921-929.	0.6	7
57	Long-Term Evolution of an Untreated Primary Cutaneous Follicle Center Lymphoma of the Scalp. <i>American Journal of Dermatopathology</i> , 2010, 32, 91-94.	0.6	18
58	High-dose immunoglobulines and extracorporeal photochemotherapy in the treatment of febrile ulceronecrotic Mucha-Habermann disease. <i>Dermatologic Therapy</i> , 2010, 23, 419-422.	1.7	13
59	THERAPEUTIC HOTLINE: A rare vandetanib-induced photo-allergic drug eruption. <i>Dermatologic Therapy</i> , 2010, 23, 553-555.	1.7	19
60	TCRÎ³-Chain Gene Rearrangement by GeneScan: Incidence and Significance of Clonal Heterogeneity in SÅ©zary Syndrome. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2312-2319.	0.7	9
61	Prevalence and significance of human parvovirus variants in skin from primary cutaneous T cell lymphomas, inflammatory dermatoses and healthy subjects. <i>Archives of Dermatological Research</i> , 2009, 301, 647-652.	1.9	10
62	Flow cytometry immunophenotyping in mycosis fungoides. <i>Journal of the American Academy of Dermatology</i> , 2008, 59, 533-534.	1.2	9
63	Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients. <i>Melanoma Research</i> , 2007, 17, 75-82.	1.2	34
64	Expression Pattern of Chemokine Receptors and Chemokine Release in Inflammatory Erythroderma and SÅ©zary Syndrome. <i>Dermatology</i> , 2006, 213, 284-292.	2.1	34
65	Sentinel lymph node dissection in stage I/II melanoma patients: surgical management and clinical follow-up study. <i>Melanoma Research</i> , 2004, 14, S9-S12.	1.2	16
66	Clinical significance of sequential tyrosinase expression in the peripheral blood of disease-free melanoma patients: a review of literature data. <i>Melanoma Research</i> , 2004, 14, S17-S19.	1.2	24
67	Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 281-287.	1.2	28
68	Metastatic melanoma of the heart. <i>Journal of Surgical Oncology</i> , 2000, 75, 203-207.	1.7	52
69	"Aleukemic" Granulomatous Leukemia Cutis. <i>American Journal of Dermatopathology</i> , 1998, 20, 417-421.	0.6	36
70	Mantle zone lymphoma: An immunohistologic study of skin lesions. <i>Journal of the American Academy of Dermatology</i> , 1994, 30, 23-30.	1.2	53
71	Expression and Role of Integrin Receptors in SÅ©zary Syndrome. <i>Journal of Investigative Dermatology</i> , 1992, 99, 151-159.	0.7	11
72	Immunoglobulin DNA Analysis as a Marker of Clonality in the Follow-up of Patients with Hairy Cell Leukemia Treated with Alpha-Interferon. <i>Leukemia and Lymphoma</i> , 1990, 2, 103-110.	1.3	0

#	ARTICLE	IF	CITATIONS
73	Lymphokine-activated killer (LAK) cells inhibit the clonogenic growth of human leukemic stem cells. European Journal of Haematology, 1989, 42, 425-430.	2.2	23
74	Immunological and Molecular Classification of Human Leukemias. , 1986, , 95-101.		1
75	Immature T lymphocytes in human cord blood identified by monoclonal antibodies: A model for the study of the differentiation pathway of T cells in humans. Cellular Immunology, 1984, 89, 194-201.	3.0	42
76	Chronic T-cell leukaemias. III. T-colonies, PHA response and correlation with membrane phenotype. Leukemia Research, 1982, 6, 809-814.	0.8	11